SPHS Sophiris Bio Inc.

0.99
-0.01  -1%
Previous Close 1
Open 1.01
Price To Book 16.49
Market Cap 29888801
Shares 30,217,140
Volume 67,328
Short Ratio
Av. Daily Volume 117,320

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial planned. Phase 2b data released December 17, 2018 noted no additional benefit gained with a second administration.
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 3 primary endpoints met - November 2015. Second Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Benign prostatic hyperplasia

Latest News

  1. Sophiris Bio to Present at Two Upcoming Investor Conferences
  2. SPHS: Awaiting Regulatory Guidance for Topsalysin Phase 3 Study…
  3. Sophiris Bio Reports Fourth Quarter 2018 and Year-end Financial Results and Recent Corporate Highlights
  4. SPHS: Ready to Move Topsalysin into Phase 3 for Localized Clinically Significant Prostate Cancer…
  5. Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial
  6. Does Sophiris Bio Inc (FRA:BFF1) Have A Volatile Share Price?
  7. SPHS: Data from Second Administration of Topsalysin in Phase 2b Trial Anticipated Before End of 2018…
  8. Report: Exploring Fundamental Drivers Behind HC2, Pangaea Logistics Solutions, Sophiris Bio, Acacia Research, JAKKS Pacific, and LeMaitre Vascular — New Horizons, Emerging Trends, and Upcoming Developments
  9. Sophiris Bio to Present at the Piper Jaffray Healthcare Conference
  10. Sophiris Bio Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
  11. Sophiris Bio to Present at the Cantor Global Healthcare Conference
  12. Sophiris Bio Extends the Interest Only Period under its Loan and Security Agreement
  13. SPHS: Patient Death in Phase 2b Trial Unlikely Related to Topsalysin Treatment…
  14. Today’s Research Reports on Stocks to Watch: Opiant Pharmaceuticals and Sophiris Bio
  15. Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference
  16. Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial
  17. SPHS: Ready to Advance Topsalysin into Registration Studies…
  18. Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
  19. SPHS: Interim Data Reported for P2b Study of Topsalysin in Localized Prostate Cancer
  20. Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Sophiris